Skip to content

Impact of Low Frame Rate Fluoroscopy and Cine-angiography on Reducing Operator and Patient Dose

Impact of Low Frame Rate Fluoroscopy and Cine-angiography on Reducing Operator and Patient Radiation Dose and Impact on Image Quality During Cardiac Catheterization

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02574949
Enrollment
600
Registered
2015-10-14
Start date
2015-07-31
Completion date
2016-07-31
Last updated
2015-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Stable Angina, Unstable Angina

Keywords

radiation, fluoroscopy, diagnostic

Brief summary

The investigators sought to investigate the efficacy of low frame rate (fluoroscopy at 7.5 frames per second (FPS) and Cine at 10 pulse per second (PPS) vs. conventional (15 FPS and 15 PPS) on radiation dose to the patient and the operator during coronary angiography and intervention. In addition, investigators sought to qualitatively assess the effect, if any, of the low frame rate on angiographic image quality.

Detailed description

Minimizing radiation exposure to patient and the operator is considered one of the primary safety concerns in the catheterization laboratory. Patients undergoing diagnostic angiography +/- ad hoc PCI or planned PCI, will be randomised to conventional settings (15 FPS and 15 PPS) or low frame rate settings (7.5 FPS and 15 PPS) or low Cine settings (7.5 FPS and 10 PPS). The patient radiation dose, patient radiation dose area product (DAP), and fluoroscopy time will be measured. Statistical Analysis: Demographic and procedural variables will be presented as percentage (categorical variable) or mean ± SD (continuous variable). Patients will be randomized into three arms - a control arm and two intervention arms. The angiographic radiation protocol will adhere to standard practice in both fluoroscopy and cine images at 15 frames/second. The intervention arm will consist of two groups. Group 1 with fluoroscopy images set at 7.5 frames/second and cine images set at 15 frames/second and group 2 with fluoroscopy set at 7.5 frames/second and cine set at 10 frames/second. Sample size calculations are based on assuming a reduction in radiation dose in group 1 of 10% and in group 2 of 20%. At 5% significance and 80% power, a sample size of 200 patients will be required in each intervention arm. Allowing for a 10% attrition rate, a sample size of 220 patients will be required in each intervention arm with 100 patients in the control arm.

Interventions

RADIATIONRadiation: 15 FPS Cine 15 PPS

Radiation 15 FPS Cine 15 PPS

RADIATIONRadiation: 7.5 low Frame rate

Radiation: Frame rate 7.5 FPS, Cine 15 PPS

RADIATIONLow Cine

Radiation: Frame rate 7.5 FPS, Cine 10 PPS

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing elective or urgent cardiac catheterisation with or without ad-hoc PCI or planned PCI in the pre-specified catheterisation laboratories.

Exclusion criteria

* Patients who undergo procedures other than diagnostic coronary angiography or intervention (e.g. electrophysiological procedures). * Patients participating in other research study requiring higher cine angiography. * ST-elevation Myocardial Infarction

Design outcomes

Primary

MeasureTime frameDescription
Radiation Exposure to patientDuring Cardiac catheterization procedureRadiation exposure to patient will be measured by Dose-Area product (DAP) collected during the procedure.

Secondary

MeasureTime frameDescription
Image quality assessment of the coronary angiogram12 monthsCoronary angiograms will be assessed by blinded operators for quality of image using a pre-specified tool

Countries

Canada

Contacts

Primary ContactDivyesh Sharma, MSc,MRCP
divyeshsharma11@gmail.com001-647-961-9336
Backup ContactAshish H Shah, MD, MD(Res)
ashish.shah@uhn.ca001-416-835-2822

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026